Targeted cancer drugs to overtake chemotherapy as top-seller


Targeted cancer therapies, like Novartis AG's top-selling Gleevec, will replace chemotherapy as the most-sold cancer drugs, market researcher Datamonitor said. Targeted therapies will cut into chemotherapy's market share, which was almost half of the $20 billion cancer drug market last year, and grow to about 55% of top 20 cancer drug sales by 2015, Datamonitor said in an e-mailed statement. Medicines including Bayer AG's Nexavar, Pfizer Inc.'s Sutent, Bristol-Myers Squibb Co.'s Sprycel and Amgen Inc.'s panitumumab „all show great potential for the future treatment of cancer,” Fleur Pijpers, an oncology analyst with Datamonitor, said in the statement. Targeted therapies don't tax cancer patients as severely as conventional chemotherapy because they can distinguish cancer cells from normal cells, while chemotherapy attacks all growing cells, even healthy ones. Datamonitor analyzed 37 drugs in the UK, the US, France, Germany, Italy, Spain and Japan. The total drug market is expected to peak at $31 billion in 2010, then drop to $27 billion, Datamonitor said. Sales of antihormonal therapies, which now have a market share of 25%, will drop as patents run out and generic competitors arrive on the market. (Bloomberg)


Consumer price levels below EU avg in 2020 Analysis

Consumer price levels below EU avg in 2020

Lawmakers approve 2022 budget Parliament

Lawmakers approve 2022 budget

Breast cancer screening at Dr. Rose Private Hospital Interview

Breast cancer screening at Dr. Rose Private Hospital

Budapest launches revamped coupon card for visitors City

Budapest launches revamped coupon card for visitors


Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.